We invest in early stage health solutions leveraging the funnel of SPRIM’s sourcing, screening and selection processes.
SPRIM VENTURES benefits from SPRIM’s unique combination of skills and resouces:
Strong and long established relationships with large healthcare companies
Global infrastructure of 19 offices around the world
Potential partnerships with more than 400 global customers
Travecta Therapeutics is a company that develops novel chemistry for delivery of therapies to the brain.Travecta is based on the research of Prof. David Silver and leverages a discovery platform to identify, simplify and categorize small molecules for enabling their transport across the blood-brain barrier.
Obviohealth commercializes software solutions to help healthcare industry players substantiate health claims as well as achieve better visibility on their healthcare professional network.
ClaimIt is a proprietary digital platform that utilizes a 100% online & mobile app interface to execute clinical trials. It removes the costly overhead of physical site visits and brings the trial directly to the mobile device of each subject.
Digital Diagnostic Asia specializes in algorithm-based non-invasive diagnostic solutions. Digital Diagnostic Asia commercializes in Asia the non-invasive liver test benchmark Fibro-Test. Fibro-Test and related tests (Acti-Test, Steato-Test, NASH-Test) deliver the same diagnostic value as a 25mm biopsy without risk and at a fraction of the cost. This test based on a combination of 6 blood parameters is now established in the guidelines as the first line of diagnostic in France and is reimbursed. This range of tests are supported by over 280 studies published by 1133 authors in 89 journals.
Raffiné is a proprietary e-commerce platform for Japan. It focuses solely on skin and hair care products that deliver tangible outcomes. Raffiné owns brand such as Jeune Vie and licenses from the French cosmetic leader Eugene Perma. Raffiné is headquartered in Tokyo.
Babynostics is developing diagnostics and treatment solutions based on the research of Professor David Silver at Duke-NUS on MFSD2a and Lysophospatidylcholine (LPC) lipids. His key discovery was published in Nature on May 2014: ”Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid”.